<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700345</url>
  </required_header>
  <id_info>
    <org_study_id>MAGIC-MT</org_study_id>
    <nct_id>NCT04700345</nct_id>
  </id_info>
  <brief_title>Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment</brief_title>
  <acronym>MAGIC-MT</acronym>
  <official_title>Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Shen Kang Hospital Development Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      MAGIC-MT study is multi-center, prospective, randomized (1:1) controlled trial designed to&#xD;
      show that additional MMA embolization with Onyx in patients with non-acute symptomatic&#xD;
      subdural hematoma(SDH) results in reduced hematoma recurrence in surgically treated patients/&#xD;
      reduced hematoma progression in conservatively managed patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to show that additional MMA embolization with Onyx in patients&#xD;
      with non-acute symptomatic subdural hematoma(SDH) results in reduced hematoma recurrence in&#xD;
      surgically treated patients/ reduced hematoma progression in conservatively managed patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of symptomatic SDH recurrence/ progression within 90 days post-procedure</measure>
    <time_frame>90 days</time_frame>
    <description>SDH recurrence (&gt;10 mm max. thickness) or receiving re-operation in patients who underwent surgery/ symptomatic SDH progression (&gt;3 mm increase in max thickness or receiving surgical rescue in patients who did not undergo sugery) at 90 days&#xD;
&quot;Symptomatic&quot; is hereby defined as one or more of the following features which are attributed to the progression/recurrence: headache, short-term cognitive decline, speech difficulty or aphasia, gait impairment, focal weakness, sensory deficits, seizures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>1 year post-procedure</time_frame>
    <description>Incidence of SDH recurrence/ progression at 1 year post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>day 0</time_frame>
    <description>Rate of successful embolization of the target vessels (MMA trunk and branches) with ONYX base on DSA imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Change in hematoma thickness based on CT/MRI imaging at 90 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Changes in hematoma volume at 90 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>90 days post-procedure</time_frame>
    <description>Change in Midline shift based on CT/MRI imaging at 90 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>90 days and 1 year post-procedure</time_frame>
    <description>Change in the Modified Rankin Scale score (mRS) Grade 0 (no symptoms) to 6 (death) at 90 days and 1 year post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>90 days and 1 year post-procedure</time_frame>
    <description>Percentage of patients with favorable functional outcome defined as Modified Rankin Scale of 0 to 3 at 90 days and 1year post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>90 days and 1 year post-procedure</time_frame>
    <description>Percentage of patients with good functional outcome defined as Modified Rankin Scale of 0 to 2 at 90 days and 1 year post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>90 days and 1 year post-procedure</time_frame>
    <description>Quality of life assessed by (EuroQol) EQ-5D scale Grade 0 (worst health) to 100 (best health) at 90 days and 1 year post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>90 days</time_frame>
    <description>Total patients with SAEs within 90 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>90 days</time_frame>
    <description>Incidence of neurological death within 90 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of procedural serious complications within 30 days post-procedure:&#xD;
symptomatic procedure-related intracranial hemorrhage&#xD;
any procedure-related intracranial hemorrhage&#xD;
any procedure-related neurological deficit&#xD;
CNS infection caused by procedure&#xD;
procedure-related artery dissection, vessel wall damage and vessel perforation&#xD;
procedure-related ischemic event&#xD;
retroperitoneal hematoma (femoral access)/wrist hematoma (radial access)&#xD;
neuropathy at the puncture site&#xD;
contrast agent allergy or encephalopathy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">722</enrollment>
  <condition>Subdural Hematoma, Non-acute</condition>
  <arm_group>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle meningeal artery(MMA) embolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No embolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Onyx</intervention_name>
    <description>Embolization of the Middle Meningeal Artery using the liquid embolic material</description>
    <arm_group_label>Embolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Burr-hole</intervention_name>
    <description>Burr-hole drainage of subdural hematoma</description>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_label>No embolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Management</intervention_name>
    <description>best medical management</description>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_label>No embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic non-acute SDH with mass effect (i.e. chronic or subacute SDH, fulfilling&#xD;
             one or more of the following criteria)&#xD;
&#xD;
               1. &lt;30% hyperdense components&#xD;
&#xD;
               2. septations that are indicative of a chronic SDH&#xD;
&#xD;
               3. known from previous (&gt;2 weeks old) brain imaging Mass effect is defined as&#xD;
                  midline shift or deformation of the normal contour of the brain (i.e. flattening)&#xD;
                  due to the SDH.&#xD;
&#xD;
             Symptomatic SDH is defined as an SDH that fulfills one or more of the following&#xD;
             criteria AND shows neurological symptoms (headache, short-term cognitive decline,&#xD;
             speech difficulty or aphasia, gait impairment, focal weakness, sensory deficits,&#xD;
             seizures) that are attributable to the hematoma&#xD;
&#xD;
          2. Age 18 or higher&#xD;
&#xD;
          3. Independent functional status in activities of daily living with mRS score ≤ 2 prior&#xD;
             to the symptom.&#xD;
&#xD;
          4. Signed informed consent or appropriate signed deferral of consent where approved.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Qualifying imaging reveals clear hypodense demarcation of the majority of the&#xD;
             territory of symptomatic intracranial occlusion.&#xD;
&#xD;
          2. Subject requires (in the opinion of the treating surgeon) a full or mini craniotomy.&#xD;
&#xD;
          3. Subject with urgent or emergent subdural hematoma evacuation needed.&#xD;
&#xD;
          4. Bilateral SDH with unknown origin of symptoms.&#xD;
&#xD;
          5. Any evidence of anatomical variants that might render safe MMA embolization impossible&#xD;
             (e.g. prominent MMA-ophtalmic artery anastomoses)&#xD;
&#xD;
          6. Coagulation and platelet disorders, or antiplatelet medication that is not easily&#xD;
             correctable with INR &gt;1.5 and/or platelet count &lt; 80.000.&#xD;
&#xD;
          7. Contraindications for neurangiography, e.g. iodinated contrast allergy, renal&#xD;
             insufficiency with GFR &lt; 30 ml/min.&#xD;
&#xD;
          8. CT or MRI evidence of intra-cranial tumor or mass lesion.&#xD;
&#xD;
          9. Pregnancy; if a woman is of child-bearing potential a urine or serum beta HCG test is&#xD;
             positive.&#xD;
&#xD;
         10. Patient has a severe or fatal comorbid illness that will prevent improvement or&#xD;
             follow-up or that will render the procedure unlikely to benefit the patient.&#xD;
&#xD;
         11. Life expectancy &lt;1 year.&#xD;
&#xD;
         12. High risk of removal from antiplatelet and/or anticoagulant medical therapy for recent&#xD;
             procedure or other reasons.&#xD;
&#xD;
         13. Patient cannot complete follow-up for any reason. (eg. visiting from another city,&#xD;
             illness, incarceration in prison etc.)&#xD;
&#xD;
         14. Participation in another clinical trial investigating a drug, medical device, or a&#xD;
             medical procedure that might confound treatment and outcomes related to the current&#xD;
             trial.&#xD;
&#xD;
         15. Previous surgery or endovascular treatment for the SDH under investigation&#xD;
&#xD;
         16. Unable to undergo MMA embolization prior to surgical treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Mao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>department of Neurosurgery, Huashan Hospital,Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Min Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>department of Neurosurgery, Changhai Hospital of the Second Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuxiang Gu, PhD</last_name>
    <phone>+8613801847125</phone>
    <email>guyuxiang1972@26.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Ni, PhD</last_name>
    <email>hsniwei@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuxiang Gu</last_name>
    </contact>
    <investigator>
      <last_name>Ying Mao, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianmin Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Ying Mao</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

